GHRL and Alzheimer disease: ghrelin agonist LY444711acted as a neuroprotective via insulinsignaling pathways in the hippocampus, this included decreasing theexpression of phosphorylated insulin receptor substrate 1 (p-IRS Ser636) which has been shown to be associatedwith AD